Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients
Brief Summary: The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.


Options:
A: Arm Label: Mycophenolate sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus | Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus | Intervention Type: DRUG; Name: Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus; Assigned to Arm(s): Mycophenolate sodium
B: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
C: Arm Label: 1: Myfortic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Sodium Delayed Release Tablets | Arm Label: 2. Cellcept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate Mofetil | Intervention Type: DRUG; Name: Mycophenolate Sodium Delayed Release Tablets; Assigned to Arm(s): 1: Myfortic | Intervention Type: DRUG; Name: Mycophenolate Mofetil; Assigned to Arm(s): 2. Cellcept
D: Arm Label: EVR+rCNI; Type: EXPERIMENTAL; Interventions: Biological: Induction therapy, Drug: Corticosteroids, Drug: EVR+rCNI | Arm Label: MPA+sCNI; Type: ACTIVE_COMPARATOR; Interventions: Biological: Induction therapy, Drug: Corticosteroids, Drug: MPA+sCNI | Intervention Type: BIOLOGICAL; Name: Induction therapy; Assigned to Arm(s): EVR+rCNI, MPA+sCNI | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR+rCNI, MPA+sCNI | Intervention Type: DRUG; Name: EVR+rCNI; Assigned to Arm(s): EVR+rCNI | Intervention Type: DRUG; Name: MPA+sCNI; Assigned to Arm(s): MPA+sCNI

Answer: B